Science

Jan 14, 2025, 18:51

Abi Siva: Another step close to De-escalation

Abi Siva, Associate Professor and Director of Medical Oncology at MUSC Hollings Cancer Center, shared a recent article by Xiu-Chun Chen, et al. on X:

“Another step close to De-escalation.

Neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus TCHP in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial – The Lancet Oncology.”

“De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial“

Authors: Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, Cheng-Zheng Wang, Xian-Fu Sun, Zhen-Duo Lu, Lian-Fang Li, Chong-Jian Zhang, Min Yan, Ya Wei, Bo Chen, Yue-Qing Feng, Miao Deng, Ming-De Ma, Professor Jennifer K Plichta, Professor You-Wen He and Zhen-Zhen Liu

De-escalation

For more updates, follow OncoDaily.

Abi Siva Breast Cancer cancer Cheng-Zheng Wang De-Chuang Jiao de-escalation Jiang-Hua Qiao MUSC Hollings Cancer Center OncoDaily Oncology The Lancet Oncology Xian-Fu Sun Xiu-Chun Chen Zhen-Zhen Liu

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage